Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
XW LABORATORIES
{{company.company_channel.channel_name}}
Media Room
Latest
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
FDA Grants Orphan Drug Designation to XW Laboratories' XWL-008 for the Treatment of Patients with Narcolepsy
2019-06-24 17:00
XW Labs Appoints Clinical Development Veteran Dr. Daniel Canafax as Chief Medical Officer
2018-09-10 17:00
XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment
2018-03-12 17:00
XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment
2018-03-12 17:00
XW Labs secures over $17M Series B financing led by Elements Capital and WI Harper
2017-09-20 17:00
XW Labs Announces Exclusive Licensing Agreement with University of Pittsburgh to Develop Novel Mitochondria-Targeting Compounds
2017-03-06 18:00
1